117 results about "Multiple cancer" patented technology

The present invention provides the isolation and cloning of WWOX, a novel WW domain-containing protein mapping to human chromosome 16q23.3-24.1, a region frequently affected in several cancers. This gene encodes a tumor suppressor with apoptotic functions. The invention provides WWOX nucleic acid- and polypeptide-based cancer therapies. The invention also provides methods for cancer detection, diagnosis and prognosis involving WWOX nucleic acids and polypeptides.

The present disclosure relates to a fusion nano liposome-fluorescence labeled nucleic acid in which a bead having a surface binding with a branch-shaped nucleic acid structure labeled with a fluorophore or a branch-shaped nucleic acid structure having a hairpin loop end is included in an inside of a liposome, and a diagnosis application thereof. The fusion nano liposome-fluorescence labeled nucleic acid, or fusion nano liposome-fluorescence labeled hairpin loop structured nucleic acid may sense an external or internal signal, and high-sensitive diagnosis is possible even when mRNA and miRNA which is present at a low concentration in cells being targeted. Further, various target materials expressed inside and outside of a cell membrane may be targeted, and thus even a type of cancer which is hard to diagnose such as triple negative breast cancer also be flexibly diagnosed. Further, using various fluorophores, multiple cancer may be diagnosed at the same time.

The invention discloses a CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)-Cas9 system capable of simultaneously knocking out KRAS genes and EGFR genes. The system comprises sgRNA for specifically targeting KRAS genes and sgRNA for specifically targeting EGFR genes, wherein a corresponding DNA sequence of the sgRNA for specifically targeting KRAS genes is shown as SEQ ID NO.1 or / and SEQ ID NO.2; and a corresponding DNA sequence of the sgRNA for specifically targeting EGFR genes is shown as SEQ ID NO.11 or / and SEQ ID NO.12. The invention further discloses application of the system in preparation of medicines for treating cancers. The CRISPR-Cas9 system disclosed by the invention is capable of simultaneously and efficiently knocking out two cancer driving factors KRAS and EGFR which are highly-expressed in lung cancer. The system is simple in operation and high in knockout efficiency and is expected to be applied to treatment of the lung cancer. The system disclosed by the invention is applicable to multiple cancers with abnormal expressions of the EGFR and KRAS.

The invention provides a method for inhibiting proliferation of cancer cells, as well as methods for detecting and treating various cancers, including cancer of the brain, lung, breast, prostate and colon. The method comprises contacting a cancer cell with a molecule that disrupts the biological activity of a GDOX molecule. In one embodiment, the molecule is an antibody directed against a GDOX peptide. In other embodiments, the molecule is an antisense nucleotide directed against a GDOX nucleic acid molecule, or a vaccine comprising a GDOX peptide or a polynucleotide encoding a GDOX peptide. The invention additionally provides methods for detecting and treating cancer using GDOX-related molecules.

Apparatuses (including devices and systems) and methods for determining if a patient will respond to a variety of cancer drugs.

The invention relates to corydalis and corydalis of isodon macrophylla which are extracted and separated from the isodon macrophylla and have the structural formula of ent-abietane diterpenoids, a preparation method and applications thereof. A plurality of in vitro anti-tumor activity experiments show that the compounds have significant effect of inhibiting the activity of tumor cells and can be applied in the preparation of medicaments for treating cancers and / or tumors. The invention can also provide the lead compounds for developing new medicaments for treating various common multiple cancers, thereby having important significance on developing and utilizing medicinal plant resources of China.

A novel gene (designated 158P1D7) and its encoded protein are described. While 158P1D7 exhibits tissue specific expression in normal adult tissue, it is aberrantly expressed in multiple cancers including set forth in Table 1. Consequently, 158P1D7 provides a diagnostic and / or therapeutic target for cancers,. The 158P1D7 gene or fragment thereof, or its encoded protein or a fragment thereof, can be used to elicit an immune response.

The invention relates to a biological detection method, and particularly relates to a diacetyl spermine detection kit and a preparation method thereof. The diacetyl spermine detection kit comprises a test strip, wherein the test strip sequentially comprises a glass cellulose film, a gold pad, an NC film and absorbent paper from a sample charging end. The diacetyl spermine detection kit is characterized in that monoclonal antibodies of DiAcSpm and CRE labeled by colloidal gold and a rabbit antibody are coated on the gold pad; a detection region (T) on the NC film has antigens of the DiAcSpm and the CRE, and a standard region (C) has a goat anti rabbit antibody. According to the diacetyl spermine detection kit, by applying principles of cytobiology, molecular biology, biochemistry, immunology and the like, using a colloidal gold immunochromatography technology, and adopting single methods such as urinalysis and the like which are easy to operate and noninvasive, a diacetyl spermine in vitro diagnosis kit for early discovery and early diagnosis of diacetyl spermine in urine of patients suffering from multiple cancers can be obtained. The detection is performed by using a colloidal gold immunochromatography analyzer, and the purposes of rapidness, accuracy and convenience in operation are achieved.

The invention discloses a high-throughput prediction method for neoantigens of pan-cancer tumor and application thereof. According to the prediction method disclosed by the invention, mutation and MHC(Major Histocompatibility Complex) detection are carried out on the basis of a next-generation sequencing original data file, and candidate tumor neoantigens are scored from multiple dimensions, so that the false positive of neoantigen screening can be reduced, and the neoantigens with high credibility can be screened out through scoring sorting. The method disclosed by the invention can be suitable for multiple cancer species, can predict the tumor neoantigen without distinguishing the cancer species, and lays a foundation for immunotherapy based on the tumor neoantigen.

The invention belongs to the fields of organic chemistry and pharmaceutical chemistry and particularly relates to novel disulfide compounds shown as a formula I as well as a synthetic method and application of the novel disulfide compounds. The disulfide compounds have strong inhibiting function for various tumor cells and can be used as pilot compounds for researching novel tumor-resisting medicaments or can be used as medicaments for treating various clinically-general multiple cancers. The formula I is shown as the description.

The present invention relates to Tri-Specific Binding Molecules, which are multi-chain polypeptide molecules that possess three Binding Domains and are thus capable of mediating coordinated binding to three epitopes. The Tri-Specific Binding Molecule is preferably characterized in possessing binding domains that permit it to immunospecifically bind to: (1) an epitope of a first Cancer Antigen, (2) an epitope of a second Cancer Antigen, and (3) an epitope of a molecule that is expressed on the surface of an immune system effector cell, and are thus capable of localizing an immune system effector cell to a cell that expresses a Cancer Antigen, so as to thereby facilitate the killing of such cancer cell.

The invention relates to the medicine technical field, in particular to lanostane triterpenoid compound sexangulic acid extracted and separated from a Chinese mangrove plant Bruguiera sexangula, derivatives, a preparation method and a use thereof. The structural formula of the sexangulic acid and the derivative thereof are shown in the following formula, when R1 and R2 are simultaneously hydrogen, the compound is the sexangulic acid. A plurality of in vitro anti-tumor activity tests prove that the compound and the derivative thereof can obviously inhibit tumor cell activity and are expected to be applied to preparing anti-cancer drugs. The invention can provide a lead compound for developing new medicines for treating various common multiple cancers, and plays an important role in developing and utilizing living marine resources in China.

The invention relates to an alcohol extract of walnut kernel and a use thereof, effectively developing a new use of the alcohol extract of walnut kernel capable of inhibiting propagation of nerve tumour cells and applicable to the preparation of anti-tumour medicines to control propagation of tumour cells. The inventive alcohol extract of walnut kernel is prepared by the following steps: soaking the walnut kernel in absolute ethyl alcohol for one weak, the weight of which is 4-10 times of that of the absolute ethyl alcohol; filtering the solution to obtain medical liquid; condensing the medical liquid at 55-65 DEG C; drying the medical liquid in a vacuum environment at 55-65 DEG C to obtain 7.34% of brown oil-form alcohol extract of walnut kernel; while storing, dissolving the obtained extract by dimethyl sulfoxide into storage liquid, the concentration of which is 300 mug / mul; and storing the storage liquid in a refrigerator at -20 DEG C for standby use. In experiment, the storage liquid is prepared into needed concentration by serum-free culture medium that satisfies demand of cultured cells; and the storage liquid is filtered to remove bacteria therein and is added with serum. Experiment shows that the inventive alcohol extract of walnut kernel has function of inhibiting propagation of multiple cancer cell strains and is expected to be a new product for research on anti-cancer medicine development.

The invention belongs to the technical field of food, and particularly discloses low-sugar raspberry composite jam and a preparation method thereof. The low-sugar raspberry composite jam comprises the following components in parts by weight: 280-320 parts of black raspberry fruits, 90-110 parts of red raspberry fruits, 300-350 parts of carrots, 2-4 parts of red dates, 2-5 parts of medlar fruits, 3-6 parts of aloes, 1-5 parts of cherries, 150-200 parts of white granulated sugar, 4-6 parts of low methoxyl pectin, 0.5-1.0 part of CaCl2 and 0.10-0.20 part of xanthan gum. The preparation method comprises the steps of rinsing, pulping, blending, vacuum concentration, vacuum packaging and ultrahigh pressure sterilization. The low-sugar raspberry composite jam provided by the invention has the functions of resisting aging, beautifying, balancing blood pressure, improving eyesight, treating gastrointestinal diseases and preventing multiple cancers, tastes sweet and acidy, and is good for people of all ages; the preparation method utilizes techniques of low-temperature vacuum concentration and ultrahigh pressure sterilization, and therefore nutrient substances in the raw materials are protected from damage.

The invention discloses a function-driven multi-molecular marker for individualized prediction of colorectal cancer prognosis and a device and an evaluation method thereof. Prognostic predictive markers are simultaneously screened from multiple cancer large sample data sets of multiple centers, and predictive effects of the multi-molecular marker are validated and comprehensively evaluated in three independent data sets. The application of the above methods and strategies ensures the reliability of the multi-molecular marker in judgment of the prognosis of a colorectal cancer patient; the multi-molecular marker combination is not affected by the batch effect of an experiment or the difference of a detection platform, thereby ensuring the stability of the multi-molecular marker in the judgment of the prognosis of the colorectal cancer patient; the multi-molecular marker combination does not need to be subjected to data standardization between multiple samples before use, thereby facilitating the use and ensuring the clinical operability of the multi-molecular marker in the judgment of the prognosis of the colorectal cancer patient.

The invention discloses an amide compound and an application thereof in treating cancer, and belongs to the field of pharmaceutical chemistry. The invention discloses the application of amide compoundshown in formula I, or crystal form, or stereoisomer, or isotope body, or tautomer, or pharmaceutically-acceptable salt, or solvate, or pro-drug, or metabolite thereof in treating cancer. Experimental results show that the compound can inhibit the proliferation of prostate cancer cells, especially has an obvious inhibition effect on drug-resistant prostate cancer cell line (22RV1). At the same time, the compound can obviously inhibit the proliferation of multiple cancer cells. In addition, the compound has good pharmacokinetics, which has a potential therapeutic effect on cancer, especially prostate cancer, and provides a new choice for clinical screening and / or preparation of cancer drugs.

A diagnostic technique for matching anti-cancer peptide drugs to the molecular profiles of individual cancer tumors, and a method using the technique for a patient-specific treatment of tumors in mammals. This strategy matches anti-cancer peptide drugs to the molecular profiles of individual tumors, and includes the development of two banks, both of which use the same targeting peptides. Targeting peptides are identified using biopsies or other tissue materials from multiple cancer patients and placed into two banks. For a bank of probes, targeting peptides are linked to a label such as a fluorescent or a radioisotope. For a bank of drugs, targeting peptides are linked to a cytotoxic peptide to form a “targeting peptide drug”. Peptide probes are used to establish molecular profiles of individual tumors. Based on these molecular profiles, a patient-specific combination of targeting drugs from the bank of peptide drugs is prepared and the patient is treated. Any currently used cytotoxic agent that can be linked to targeting peptides may be used in place of cytotoxic peptides.

The invention relates to a quinazoline derivative and a preparation method and application thereof, and belongs to the technical field of medicinal chemistry. The structure of the quinazoline derivative is as shown in a formula I. The quinazoline derivative or a pharmaceutically acceptable salt thereof has an irreversible inhibition effect on tyrosine kinase, the compound can inhibit two kinds of tyrosine kinase of EGFR and HER2 simultaneously, and the compound has good inhibitory activity on multiple cancer cell lines. Please see the formula I in the description.

The invention discloses a method for synthesizing an anti-form stilbene compound and the application of the method in preparing anti-tumor medicines. According to the method, diketene and amine are in full reaction to compound N-substituent-3-oxobutanamide; then N-substituent-3-oxobutanamide is reacted with carbon disulfide and methyl iodide successively through one-pot reaction to compound alpha-oxo ketene dithioacetals; further, the alpha-oxo ketene dithioacetals is in condensation with replacement cinnamyl aldehyde to obtain alpha-((2E.4E)-5-aryl-2, 4-pentylene acyl) ketenedithioacetals; and finally, the anti-form stilbene compound is obtained through <5+1> aromatization reaction. Compared with the traditional method, according to the method, cis-isomer is avoided, the synthetic production and the utilization ratio of raw materials are high, the raw materials are chip and easy to obtain, the method and processing equipment are simple and feasible, and mass production is easy to realize. A stilbene derivative in this method has a notable restriction effect on multiple cancer cells, so that the stilbene derivative can be used for preparing the anti-tumor medicines, and the method has a high medical value and a wide market prospect.

The invention provides a broad spectrum anticancer vegetable drug, a preparation method and application thereof, belonging to the drug field; the drug takes vegetable total polysaccharide in vegetable betelnut extract, or takes the vegetable betelnut extract which takes the vegetable total polysaccharide as main component as drug active ingredients, and the vegetable betelnut extract contains more than 70 percent of the vegetable total polysaccharide; the invention further provides a preparation containing the drug active ingredients and is powder injection mainly for carrying out local direct-puncturing to malignant tumors, the preparation is composed of betelnut water extract powder and 0.9 percent of sodium chloride injection, and the drug concentration is 50mg / ml-500mg / ml. the drug has strong anticancer effect, the malignant tumors can be eliminated by local direct-puncturing by one injection. The drug can act on the multiple cancers effectively, has low toxic and side effect and provides a new concept for conquering cancers for human body.

The present disclosure provides monoclonal antibodies against protein programmed cell death 1 (PD-1), which an block the binding of PD-1 ligands to PD-1, and therefore block the inhibitory function of PD-1 ligands on PD-1 expressing T cells. The antibodies of disclosure provide very potent agents for the treatment of multiple cancers via modulating human immune function.

A novel gene (designated 121P1F1) and its encoded protein are described. While 121P1F1 exhibits tissue specific expression in normal adult tissue, it is aberrantly expressed in multiple cancers including prostate, bladder, kidney, brain, bone, cervical, uterine, ovarian, breast, pancreatic, stomach, colon, rectal, leukocytic, liver and lung cancers. Consequently, 121P1F1 provides a diagnostic and / or therapeutic target for cancers, and the 121P1F1 gene or fragment thereof, or its encoded protein or a fragment thereof used to elicit an immune response.

The invention discloses a Chinese medicinal composition for treating cancers. The Chinese medicinal composition is prepared from the following raw materials: Chinese angelica, crude astragalus, double blossom, dandelion, dahurian angelica root, platycodon root, stiff silkworm, coptis root, weeping forsythia, cicada shell, scrophularia, buffalo horn powder, apricot kernel, liquoric root, spreading hedyotis herb, large-head atractylodes rhizome, Chinese ephedra, pangolin, lucid ganoderma, common anemarrhena, divaricate saposhnikovia root, white mulberry boot-bark, barbed skullcap herb, red ginseng, whole worm, common bletilla tuber, moschus, long-noded pit viper and centipede. A preparation method of the Chinese medicinal composition is a decoction method. The Chinese medicinal composition has the effects of clearing away heat and toxic materials, promoting blood circulation to remove blood stasis, reducing swelling, removing stasis, strengthening body resistance, eliminating evil, playing a synergistic action on cancers viruses and killing cancers cells, can be used for effectively treating multiple cancers, can be used for treating both symptoms and root causes, and is remarkable in clinical treatment effect.

The invention belongs to the field of high molecular medicaments, and discloses an anticancer medicament which has targeting properties on multiple cancer cells and contributes to bonding of polyphosphate ester with paclitaxel, and a preparation method thereof. The invention specifically discloses a paclitaxel-polyphosphate ester-folic acid bonded high molecular medicament which is self-assembledin a phosphoric acid buffer solution, so that a micelle in which folic acid is distributed on an outer layer is formed. On one hand, the high hydrophobic property of a paclitaxel medicament can be improved, so that the transplant reactions of a medicament in an in-vivo conveying process are avoided; and on the other hand, the accumulation of the medicament on cancer cells is enhanced, damages of the medicament to other normal cells of tissue organs are avoided, the degrading speed of a polymer in under an in-vivo circulating condition (the pH value is about 7.4) is slow, polyphosphate ester is degraded at a higher speed due to the falling of the pH value in the presence of in-vivo bio-enzymes after the medicament reaches the cancer cells, the medicament is released, and the effect of treating tumors is achieved.

The invention discloses a novel peptide deformylase inhibitor containing spiro-three-membered ring and spiro-five-membered ring types. The novel peptide deformylase inhibitor containing the spiro-three-membered ring and spiro-five-membered ring types has antibacterial activity and anti-tumor activity. The peptide deformylase inhibitor containing the spiro-three-membered ring and spiro-five-membered ring types can serve as a novel antibacterial agent, by inhibiting the activity of peptide deformylase needed in synthesis of bacterium proteins, the novel peptide deformylase inhibitor is effective on multiple antibiotic resistant Gram-positive bacterium strains, the synthesis process of proteins of human bodies is not affected, and accordingly bacteria are killed selectively. The peptide deformylase inhibitor containing the spiro-three-membered ring and spiro-five-membered ring types can further serve as a novel anti-cancer drug; by inhibiting peptide deformylase in mitochondria of cancer cells, energy balance of the cells can be affected, accordingly mitochondrial membranes are depolarized, ATP is used up, and cell apoptosis is promoted; and the novel peptide deformylase inhibitor has good inhibiting activity to multiple cancer cell bacterial strains such as colorectal cancer cell bacterial strains, lung cancer cell bacterial strains, gastric cancer cell bacterial strains and liver cancer cell bacterial strains at the low concentration.